Haemophilia · 2000 · 175 citations · 14 references
MedicineOrthopaedic SurgeryOrthopedic SurgeryClinical EpidemiologyHealth AssessmentOrthopedicsDisease BurdenHealth-related Quality Of Life MeasurementHemolytic DisordersHemostatic DisordersMorbidity AnalysisDirect Treatment CostsEpidemiological MeasurementJoint Disease In HemophiliaOrthopaedic ComplicationsOutpatient Visit FrequencyPhysical Function MeasurementShort Form Health SurveyTreatment-related Complication Costs
One hundred and 16 patients contributed to an analysis of the impact of the consequences of severe haemophilia A or B (factor levels < 2%) on orthopaedic status, resources consumed in relation to this status and resultant cost, and quality of life as perceived by the patient, using the MOS 36-Item-Short-Form Health Survey (SF-36). This French cross-sectional study involved outpatients regularly attending a haemophilia treatment centre. Data were collected retrospectively over a period of 1 year by the physician of the haemophilia treatment centre. Patients had a mean age of 23, and consisted of 50% students, 25% salaried workers, 17.2% with no professional activity and 7.8% physically impaired; 82.8% of them had type A haemophilia. Mean pain score was 2.5 per patient for the six main joints; 7.7 for the clinical score and 18.8 for the radiological score, with a mean number of bleeds of 16.3 per year per patient. During the year prior to inclusion, and because of their orthopaedic status, 22.4% of patients were hospitalized, 76.7% attended for an outpatient visit and 76.7% required at least one special investigation; 97.4% received replacement therapy, 41.4% required treatment for joint pain and 42.2% orthopaedic equipment. The less affected dimensions were the physical function (76.8 +/- 22. 2) and the social relations (76.1 +/- 23.1). Least good quality of life scores concerned the pain (60.2 +/- 25.2), perception of general health (59.3 +/- 23.1) and vitality (57.8 +/- 19.5) dimensions. The age was a discriminant criterion since quality of life was better in patients of the 18-23 age group for five dimensions. Mean annual treatment costs of a patient with severe haemophilia were determined as 425 762 French francs ($73 029). Loss of production was estimated at a mean of 4609 French francs ($791) per active patient over the course of the year. Results showed indirect evidence of the usefulness of early home treatment.
14
The MOS 36-ltem Short-Form Health Survey (SF-36)
John E. Ware, Cathy D. Sherbourne · Medical Care · 1992 · 29.8K citations
Haemophilia prophylaxis in young patients–a long‐term follow‐up
Thomas Löfqvist, Inga Marie Nilsson, Erik Berntorp et al. · Journal of Internal Medicine · 1997 · 338 citations · Full text